Windward Bio raises USD 165 M

Windward Bio develops antibodies against immunological diseases, including WIN378, an anti-TSLP in phase 2/3 testing in asthma. It has raised USD 165 million in a crossover round led by OrbiMed to advance its clinical programmes.

Announced on
Round
Undisclosed round
Amount
USD 165 M
Location
Basel, canton of Basel-Stadt
Sector
Biotech & life sciences

Investors

  • OrbiMed lead
  • Novo Holdings
  • Blue Owl Healthcare Opportunities
  • SR One
  • Omega Funds
  • RTW Investments
  • Qiming Venture Partners
  • Quan Capital
  • Pivotal bioVenture Partners
  • RA Capital Management
  • Janus Henderson Investors
  • Sanofi Ventures
  • Harbour BioMed

Preparing a similar round?

The diagnostic shows you the instruments and investors that fit your stage.

Start the diagnostic